Navigation Links
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer

ht; position: relative;">

"AV-412 showed potent inhibition of the EGFR L858R mutations and, in two well-established animal models, demonstrated dose-dependant tumor regression in both small and large lung tumors and complete regression of lung tumors at a dose where erlotinib is inactive," said Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals. "These data, while early, highlight the promise of AV-412 as an option for lung cancer patients who carry the EGFR L858R mutation, as well as patients who become resistant to first-generation tyrosine kinase inhibitors. We are looking forward to initiating Phase 2 trials as soon as we establish an appropriate dose in the current Phase 1 study, which was initiated last October."

To provide robust models for translational research supporting the development of novel agents for lung cancer, AVEO generated a series of inducible mouse lung cancer models using AVEO's Human Response Prediction(TM) Platform. Using this proprietary platform, AVEO generated several different models covering the most prevalent oncogenic mutations including EGFR(L858R), EGFR(L858R/T790M) and KRAS(G12V). Unlike studies in primary genetically engineered tumor models, this approach enables the quantitative and comparative analysis of different drugs, doses, schedules and combinations to optimize drug selection and clinical trial design in the clinic.

Utilizing these novel models, AVEO evaluated the activity of AV-412 in non-small cell lung cancer tumors. Data presented today at the AACR meeting show that AV-412 is highly active against tumors from the chimeric model carrying the EGFRL858R mutation, exhibiting an ED50 of 0.1 mg/kg as a daily dose. AV-412 is greater than 10 times more potent than erlotinib in this model, one mg/kg PO AV-412 resulted in complete tumor regression, whereas erlotinib is active at 10mg/kg, but inactive at 1mg/kg. More importantly, AV-412 was found to be active against tumors from chimeric lung adenocar
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... 15, 2011 Awarepoint Corporation , today announced ... the company four additional patents, which brings their total ... the leading innovator of real-time wireless location systems (RTLS) ... The new patents broadly cover Awarepoint,s most accurate ...
... According to a new report published by Transparency Market ... Cardiovascular Monitoring & Diagnostic Devices Market   ... & diagnostic devices market is estimated to be USD 797 ... in 2016 at a CAGR of 8.8% over the period ...
Cached Medicine Technology:Awarepoint Advances Industry Leadership with New Patented Technology 2The Global Cardiovascular Monitoring & Diagnostic Devices Market is Booming: Expected to Attain a Market Size of USD 1.3 Billion by 2016 2The Global Cardiovascular Monitoring & Diagnostic Devices Market is Booming: Expected to Attain a Market Size of USD 1.3 Billion by 2016 3The Global Cardiovascular Monitoring & Diagnostic Devices Market is Booming: Expected to Attain a Market Size of USD 1.3 Billion by 2016 4The Global Cardiovascular Monitoring & Diagnostic Devices Market is Booming: Expected to Attain a Market Size of USD 1.3 Billion by 2016 5
(Date:10/22/2014)... Although there are only 24 hours in a day, ... have trouble finding time within their busy schedules for exercise and ... of time to get in shape. Here are five ways you ... , Change Up Your Commute , Consider riding a bike ... exercise into your daily routine. If you must use your car ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... Two sisters in high school have developed ways to ... Krishen use electronic stethoscopes, which electronically amplify body sounds, ... or heartbeats. Ilina, a senior at Port Huron ... way to detect early lung damage in people exposed ... recorded one breath cycle each from 16 smokers, 25 ...
(Date:10/22/2014)... -- Measures taken by Firestone officials at the company,s ... limited the spread of the disease there and could ... Rubber Co. provides health services to about 80,000 employees, ... communities. Between Aug. 1 and Sept. 23, there ... 80,000 people. That incidence rate of 0.09 percent was ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... American Heart Association extend their sympathy to the family and friends ... , "It,s a shame when someone his age dies so ... "Although we don,t know all the details of the situation, ... react quickly. Our thoughts and prayers are with the Jackson ...
... BOTHELL, Wash., June 25 Verathon(R), the maker of BladderScan(R) ... company,s selection, for the third year in a row, as ... State. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20061011/SFW044LOGO ) , ... for 16th "Best Company To Work For" in the mid-size ...
... Association said Thursday that pop singer Michael Jackson,s death at ... arrest, which kills nearly 300,000 Americans each year and is ... cardiac arrest (SCA) is the result of an electrical disruption ... It can strike seemingly healthy individuals without warning, including ...
... warns of potential shortage of one pain reliever , THURSDAY, ... and drug ingredients at a Michigan-based manufacturer by the U.S. ... a particular type of pain reliever, the agency said on ... products from plants run by Caraco Pharmaceutical Laboratories Ltd in ...
... ... , ... (PRWEB) June 25, 2009 -- Two grocery checkers--a 28-year-old female triathlete and a 53-year-old ... identical. Which employee will return to work sooner? Is there anything you can do ...
... Providence Service Corporation (Nasdaq: PRSC ) today ... Inc., have certified the voting results of the Company,s ... preliminary results reported by Providence on June 15, 2009. ... a wide margin, re-elected to the Providence Board of ...
Cached Medicine News:Health News:American Heart Association Extends Sympathy to Family of Singer Michael Jackson 2Health News:Verathon Recognized, Third Year in a Row, as Outstanding Workplace in Washington State 2Health News:FDA Seizes All Drugs From Generics Maker 2Health News:MDGuidelines Offers New Predictive Modeling Feature 2Health News:MDGuidelines Offers New Predictive Modeling Feature 3Health News:MDGuidelines Offers New Predictive Modeling Feature 4Health News:Providence Service Corporation Announces Certified Voting Results of Annual Meeting of Stockholders 2Health News:Providence Service Corporation Announces Certified Voting Results of Annual Meeting of Stockholders 3
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
Medicine Products: